H U : Notice of Conclusion of Agreement on Business Transfer by Consolidated Subsidiary of H.U. Group (Progress in Disclosure Item)

December 15, 2021

For Immediate Release

Company name:	H.U. Group Holdings, Inc.
Representative:	Shigekazu Takeuchi, Director,
	President and Group CEO
Securities code:	4544 First Section,
	Tokyo Stock Exchange
Contact:	Atsuko Murakami,
	Executive Officer and CFO
Telephone No.:	[phone]

Notice of Conclusion of Agreement on Business Transfer by Consolidated Subsidiary of H.U.

Group (Progress in Disclosure Item)

H.U. Group Holdings, Inc. (hereinafter the "Company") hereby announces that Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), a consolidated subsidiary of the Company, concluded the Agreement on Business Transfer with Yamasa Corporation (President: Naoyuki Ishibashi; Head Office: Choshi-shi, Chiba; hereinafter "Yamasa") for transferring a part of the business of manufacturing and selling Fujirebio's radioimmunoassay (hereinafter "RIA"*) products to Yamasa as informed in an earlier release. Details are as follows.

1. Purpose of the business transfer

As disclosed in the Notice of Conclusion of Basic Agreement on Business Transfer by Consolidated Subsidiary of H.U. Group dated May 31, 2021, the Company defined "driving fixed-cost optimization through a focus on select manual product lines" as a key initiative in the IVD business under the medium-term plan, "H.U. 2025 ~Hiyaku (significant growth) & United~," announced in September 2020. To advance this initiative, the Company decided to transfer businesses related to certain RIA products, which are a major product line in the manual product category, including their manufacture and sale, to Yamasa.

Fujirebio and Yamasa recently concluded the Agreement on Business Transfer after agreeing to terms and conditions through discussions.

2. Outline of transferee and transferor Outline of transferor

(1)	Name	Fujirebio Inc.
(2)	Location	2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo
(3)	Representative	Takeshi Fujita, President and CEO
(4)	Business	Manufacture, sale, export and import of clinical reagents and testing equipment
(5)	Capital	4.3 billion yen

Outline of transferee

(1)	Name	Yamasa Corporation
(2)	Location	2-10-1Araoi-cho,Choshi-shi, Chiba
(3)	Representative	Naoyuki Ishibashi, President
(4)	Business	Manufacture and sale of soy sauce, various seasonings and pharmaceuticals
(5)	Capital	100 million yen

3. Products subject to the transfer

1. Procollagen Intact PINP

Manufacturing and marketing authorization number: 22100AMY00001000

(2) Pyridinoline ICTP

Manufacturing and marketing authorization number: 20700AMY00152000

(3) 1,25 (OH) 2DRIA Kit 「FR」

Manufacturing and marketing authorization number: 20800AMY10137000

(4) Span-1・RIABEAD

Manufacturing and marketing authorization number: 20100AMZ00332000

4. Schedule
Business transfer	June 2023 (plan)

5. Outlook

The impact of the business transfer on our consolidated business results for the fiscal year ending March 31, 2022 is expected to be insignificant but we will promptly disclose any events arising in the future which require disclosure.

※ RIA (Radioimmunoassay): general term for immunoassay techniques using radioisotope labels